Sensei Biotherapeutics, Inc. - Common Shares, no par value per share (SNSE)
CUSIP: 81728A207
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Shares, no par value per share
- Shares outstanding
- 1,272,828
- Total 13F shares
- 69,928
- Share change
- +53,405
- Total reported value
- $599,982
- Price per share
- $8.58
- Number of holders
- 10
- Value change
- +$593,398
- Number of buys
- 9
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 81728A207?
CUSIP 81728A207 identifies SNSE - Sensei Biotherapeutics, Inc. - Common Shares, no par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 81728A207:
Top shareholders of SNSE - Sensei Biotherapeutics, Inc. - Common Shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
—
class O/S missing
|
585,576
|
$230,717 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
—
class O/S missing
|
449,963
|
$177,285 | — | 31 Mar 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
—
class O/S missing
|
294,374
|
$115,983 | — | 31 Mar 2025 | |
| Robert Hamilton Pierce |
3/4/5
|
Chief R&D Officer |
—
class O/S missing
|
94,463
|
$80,294 | — | 15 Feb 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
—
class O/S missing
|
177,300
|
$69,856 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
150,709
|
$59,393 | — | 31 Mar 2025 | |
| Erin Colgan |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
161,590
mixed-class rows
|
$53,295 | — | 15 Feb 2024 | |
| John Celebi |
3/4/5
|
PRESIDENT AND CEO, Director |
—
mixed-class rows
|
465,862
mixed-class rows
|
$50,390 | — | 19 Feb 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
108,658
|
$42,811 | — | 31 Mar 2025 | |
| Patrick Stephen Gallagher |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
34,130
|
$29,011 | — | 15 Feb 2023 | |
| Edward van der Horst |
3/4/5
|
CHIEF SCIENTIFIC OFFICER |
—
mixed-class rows
|
169,794
mixed-class rows
|
$28,462 | — | 19 Feb 2025 | |
| UBS Group AG |
13F
|
Company |
—
class O/S missing
|
42,541
|
$16,761 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
—
class O/S missing
|
25,983
|
$10,237 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
—
class O/S missing
|
25,774
|
$10,155 | — | 31 Mar 2025 | |
| Cresset Asset Management, LLC |
13F
|
Company |
—
class O/S missing
|
19,671
|
$7,750 | — | 31 Mar 2025 | |
| Deneen Vojta |
3/4/5
|
Director |
—
mixed-class rows
|
27,932
mixed-class rows
|
$7,592 | — | 11 Jun 2024 | |
| Jessie English |
3/4/5
|
Director |
—
mixed-class rows
|
27,932
mixed-class rows
|
$7,592 | — | 11 Jun 2024 | |
| Samuel Broder |
3/4/5
|
Director |
—
mixed-class rows
|
23,482
mixed-class rows
|
$7,592 | — | 10 Jul 2023 | |
| NWF Advisory Services Inc. |
13F
|
Company |
1.3%
|
16,514
|
$6,507 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
—
class O/S missing
|
14,000
|
$5,516 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
—
class O/S missing
|
9,219
|
$3,632 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
class O/S missing
|
5,404
|
$2,129 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
—
class O/S missing
|
2,558
|
$1,008 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
—
class O/S missing
|
702
|
$276 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
—
class O/S missing
|
160
|
$63 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
class O/S missing
|
142
|
$56 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
—
class O/S missing
|
124
|
$49 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
—
class O/S missing
|
92
|
$36 | — | 31 Mar 2025 | |
| Stephanie Krebs |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
120,000
|
— | — | 14 Feb 2025 | |
| Josiah Craver |
3/4/5
|
Principal Financial Officer |
—
class O/S missing
|
50,000
|
— | — | 14 Feb 2025 | |
| Bob Holmen |
3/4/5
|
Director |
—
class O/S missing
|
19,000
|
— | — | 21 May 2025 | |
| Kristian Humer |
3/4/5
|
Director |
—
class O/S missing
|
19,000
|
— | — | 21 May 2025 | |
| Thomas G. Ricks |
3/4/5
|
Director |
—
class O/S missing
|
19,000
|
— | — | 21 May 2025 | |
| William R. Ringo |
3/4/5
|
Director |
—
class O/S missing
|
19,000
|
— | — | 21 May 2025 |
Institutional Holders of Sensei Biotherapeutics, Inc. - Common Shares, no par value per share (SNSE) as of Q2 2025
As of 30 Jun 2025,
Sensei Biotherapeutics, Inc. - Common Shares, no par value per share (SNSE) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
69,928 shares.
The largest 10 holders included
VANGUARD GROUP INC, Ikarian Capital, LLC, Catalio Capital Management, LP, UBS Group AG, RAYMOND JAMES FINANCIAL INC, BANK OF AMERICA CORP /DE/, SBI Securities Co., Ltd., JPMORGAN CHASE & CO, MORGAN STANLEY, and BNP PARIBAS FINANCIAL MARKETS.
This page lists
10
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
1
Q2 2025 holders
10
Holder diff
9
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.